Objective:To study whether gangliosides inhibit the antigen-presenting capability of epidermal Langerhans cells.Methods:In the vitro test, the purified Langerhans cells were exposed to increasing concentration of gangliosides for 5 hours at 37℃,then KLH was added and incubated for 2 hours at 37℃.At last we added HDK1 and after 72 hours of coculture, levels of IFN-? in culture supernatants were measured by ELISA. In the vivo test, immunity to the S1509a spindle cell carcinoma was induced by s.c. inoculation at weekly intervals into naive syngeneic(CAF1) for a total of three immunizations. Delayed-type hypersensitivity(DTH) was elicited 1 week after the last immunization by injection a hind footpad with TAA-pulsed Langerhans cells incubated with or without gangliosides. Footpad swelling was assessed at 24 and 48 hours with a spring-loaded engineer′s micrometer.Results:The presence of gangliosides during HDK1 activation reduced the expression of IFN-? in vitro test. Gangliosides suppressed Langerhans cells to elicit DTH against TAA in vivo test.Conclusion:Ganglioside inhibit the antigen-presenting capability of epidermal Langerhans cells.

AIM: To study inhibitory effect on proliferation of docetaxel on murine angiosarcoma cell line (ISOS-1) and compare with etoposide. METH ODS: In vitro, the inhibitory effect on proliferation of docetaxel and etoposide on ISOS-1 cells were carried out by Alamar Blue assay. In vivo study, after murine angiosarcoma model establishment, seventy mice were divided into trial and control group with 5 mice for each group. The dosages of docetaxel and etoposide were 5, 10, 20 mg · kg-1 respectively through administration by intravenous (iv) or intraperitoneal (ip) injection. The iv injection was performed once a week and total 4 times as one course. The ip injection was taken once a day, keeping for 5 d as a course and then repeated once more after 2 wk. The control group was injected with the normal saline. The volumes of the tumors and the survival days were calculated. RESULTS: In vitro study, the IC5o of docetaxel for ISOS-1 cells was 15.8 μg · L-1 showing obviously lower than that of et oposide group ( 1. 175 mg · L-1 ). In vivo study, the anti-tumor effect of docetaxel was better than that of et oposide at three different doses by iv, and all the in hibitory rates of tumor volume were more than 70 %. The life prolonging effect of 5 mg · kg- 1 docetaxel was similar to that of etoposide 10 mg · kg-1. The adverse reactions of ip injection were stronger than those of ivinjection. The dosage of etoposide 20 mg · kg-1 almost reached the lethal dose. CONCLUSION: Docetaxel shows obviously inhibitory effects on proliferation of murine angiosarcoma cell line (ISOS-1), which is superior to that of etoposide. It is safe and effective with low dosage once a week by iv.

Simultaneous distillation-extractor was used for extracting the volatile substances in Phellodendron chinense Schneid.41 Volatile components were identified by gas chromatography/mass spectrometry (GC/MS) method. Of them the main components are ketones(16.38%),aldehydes(13.94%),alcohols(8.27%),phenols(50.38%),esters(3.02%),acids(2.18%).The content of the 41 identified compounds makes up 97.50% of the total volatile substances detected

Objective To understand the incidence of hemolytic disease in newborn (HDN)among the newborns with jaundice and the coincidence degree of the blood group serological results and the clinical diagnosis in HDN.Methods The microcolumn gel method was adopted to detect the 3 serological indexes in 276 jaundice newborns of maternal fetal blood group incompatibility,in-cluding the direct antiglobulin test,free antibody test and antibody release test.Results 108 cases of HDN were clinically diagnosed with the positive rate of 39.13%.The positive detection rate in newborns with 0-2 d old was highest(50.00%).Conclusion The serological test can provide the basis for the early diagnosis and treatment of HDN.Collecting the specimen as early as possible can improve the positive diagnosis rate of HDN.

Objective To investigate the synergistic effect of 11 β-hydroxysteriod dehydrogenase (11 β-HSD1) and S100A16 on the differentiation of3T3-L1 preadipocytes and its mechanism.Methods Lentiviral vectors PLJM1-11β-HSD1 and PLJM1-S100A16-GFP were respectively constructed and co-transfected into 3T3-L1 preadipocytes.The cell strains expressing 11 β-HSD1/S100A16 were screened with 2.5 μg/ml puromycin for two weeks.Western blot was employed to verify the lentiviral carrier transfection effects.The expressions of marker genes related to the adipocyte differentiation were detected by mean of realtime PCR.Oil red O staining was used to observe the lipid droplet accumulation and the content of triglyceride was measured after differentiation of preadipocytes.The effect of 11β-HSD1 and S100A16 on PPARγ promoter activity was detected by luciferase reporter gene.Results Compared with the empty vector group,the expressions of 11β-HSD1 and S100A16 protein in the lentivirus cotransfected 3T3-L1 cell strain were significantly higher.After 3T3-L1 cell strain co-expressing 1 1β-HSD1 and S100A16 was induced to differentiate for 8 days,the lipid droplets accumulation and triglyceride content were siginificantly increased,along with increased expressions of adipocyte differentiation marker genes such as PPARγ,CCAAT/enhancer binding protein α,lipoprotein lipase,fatty acid synthase,and adipocyte fatty acid-binding protein,in comparison with 11 β-HSD1 or S100A16 overexpression.The result of reporter gene indicated that 11 β-HSD1/ S100A16 enhanced PPARγ promoter activity.Conclusions 11β-HSD1 and S100A16 may jointly promote the differentiation of 3T3-L1 preadipocytes through a synergistic effect on PPARγexpression and play a critical role in the development of obesity.

Objective:To evaluate the clinical efficacy and safety of secukinumab in the treatment of moderate to severe the adults with plaque psoriasis.Methods:The clinical data from 183 adult patients with moderate to severe plaque psoriasis treated with secukinumab were collected.The patients received subcutaneous injections of secukinumab once a week at weeks 0,1,2,3,and 4,followed by an injection every 4 weeks,with each dose of 300 mg.The follow-up period was 52 weeks.The psoriasis area and severity index(PASI),body surface area(BSA),investigator global assessment(IGA),and dermatology life quality index(DLQI)scores of the patients with psoriasis were caculated.The clinical efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis were evaluated,and the influencing factors were analyzed.Results:Compared with week 0,the PASI、BSA、IGA and DLQI scores of the patients were significantly decreased at weeks 4,12,24,and 52 of secukinumab treatment(P<0.05).After treated with secukinumab,the percentages of the patients achieving PASI 75,PASI 90,and PASI 100 at week 4 were 95.6%,84.2%,and 47.5%,respectively;at week 12,they were 97.3%,95.6%,and 78.7%,respectively;at week 24,they were 97.8%,96.7%,and 84.2%,respectively;and at week 52,they were 98.4%,97.8%,and 83.6%,respectively.The percentages of the patients with BSA≤1%at weeks 4,12,24,and 52 were 80.9%,94.5%,95.6%,and 94.0%,respectively.The percentages of the patients with IGA score of 0/1 at week 4,12,24,and 52 were 86.3%,97.3%,96.7%,and 95.6%,respectively.The percentages of the patients with DLQI score of 0/1 at weeks 4,12,24,and 52 were 76.6%,89.1%,92.9%,and 91.8%,respectively.At week 4 of secukinumab treatment,there were significant differences in age,body mass index(BMI),disease duration,baseline PASI score,and history of previous biologic treatment between the patients in two groups(P<0.05).At week 24 of secukinumab treatment,there were significant differences in age and BMI between the patients in two groups(P<0.05).At week 4,BMI≥25 kg·m-2,disease duration≥10 years,baseline PASI score≥10,and a history of previous biologic treatment were risk factors affecting the recovery of the patient(P<0.05).At week 24,age≥40 years was a risk factor affecting the recovery of the patient(P<0.05).During the treatment period,44 out of 183 psoriasis patients reported 49 adverse reactions,and the adverse reaction rate was 24.0%.No serious adverse events or fatal adverse reactions occurred.The adverse reactions included upper respiratory tract infections in 23 cases,eczema-like skin lesions in 10 cases,skin fungal infections in 6 cases,urticaria in 3 cases,mild liver function abnormalities in 2 cases,folliculitis in 2 cases,conjunctivitis in 2 cases,and otitis media in 1 case.Conclusion:Secukinumab treatment for the adult patients with moderate to severe plaque psoriasis is rapid-acting and has lasting efficacy.The BMI,disease duration,baseline PASI score,history of previous biologic treatment,and age are the factors influencing the clinical efficacy of secukinumab.The overall safety is good,and secukinumab may be used as a first-line treatment option for moderate to severe plaque psoriasis.

Osteoclasts, derived from multipotent myeloid progenitor cells, play homeostatic roles in skeletal modeling and remodeling, but may also destroy bone in pathological conditions such as osteoporosis and rheumatoid arthritis. Osteoclast development depends critically on a differentiation factor, the receptor activator of NF-kappaB ligand (RANKL). In this study, we found that the hexane soluble fraction of the common fig Ficus carica (HF6-FC) is a potent inhibitor of osteoclastogenesis in RANKL-stimulated RAW264.7 cells and in bone marrow-derived macrophages (BMMs). HF6-FC exerts its inhibitory effects by suppression of p38 and NF-kappaB but activation of ERK. In addition, HF6-FC significantly decreased the expression of NFATc1 and c-Fos, the master regulator of osteoclast differentiation. The data indicate that components of HF6-FC may have therapeutic effects on bone-destructive processes such as osteoporosis, rheumatoid arthritis, and periodontal bone resorption.
Arthritis, Rheumatoid ; Bone Resorption ; Carica ; Ficus ; Macrophages ; Myeloid Progenitor Cells ; NF-kappa B ; Osteoclasts ; Osteoporosis ; Receptor Activator of Nuclear Factor-kappa B